Results 201 to 210 of about 49,838,108 (340)

Minimum capital requirement and portfolio allocation for non-life insurance: a semiparametric model with Conditional Value-at-Risk (CVaR) constraint. [PDF]

Comput Manag Sci, 2023
Staino A, Russo E, Costabile M, Leccadito A.   +3 more
europepmc   +1 more source

Methodology and Implementation of Value-at-Risk Measures in Emerging Fixed-Income Markets with Infrequent Trading. [PDF]

This paper deals with the issue of calculating daily Value-at-Risk (VaR) measures within an environment of thin trading. Our approach focuses on fixed income portfolios with low frequency of transactions in which the missing data problem makes VaR ...
Diether Beuermann, Gonzalo Cortazar, Alejandro Bernales   +2 more
core  

Extracellular vesicle lipidomics liquid biopsy reveals systemic and tumor microenvironment metabolic reprogramming in ovarian cancer

Molecular Oncology, EarlyView.
Extracellular vesicle (EV) lipidomic profiling of plasma and ascites from patients with high‐grade serous ovarian cancer and of ovarian cancer cell lines reveals enrichment of triglycerides (TGs), diacylglycerols (DGs), phosphatidylcholine (PCs), sphingomyelins (SMs), reflecting tumor metabolic reprogramming.
Shikha Rani, Dominic Guanzon, Andrew Lai, Katherin Scholz‐Romero, Sarah Reed, Edita Ritmejeryte, Rohan Lourie, Naven Chetty, Kaltin Ferguson, Carlos Salomon   +9 more
wiley   +1 more source

Left ventricular global longitudinal strain adds incremental value for risk prediction in unselected clinical patients. [PDF]

Eur Heart J Imaging Methods Pract
Backhaus SJ, Treiber JM, Wolter JS, Kriechbaum SD, Saamann D, Schuster A, Sossalla S, Rolf A.   +7 more
europepmc   +1 more source

Dependent conditional value-at-risk for aggregate risk models. [PDF]

Heliyon, 2021
Josaphat BP, Syuhada K.
europepmc   +1 more source

Worst-Case Value-At-Risk and Robust Portfolio Optimization: A Conic Programming Approach

Operational Research, 2003
L. El Ghaoui, Maksim Oks, François Oustry   +2 more
semanticscholar   +1 more source

Predictive and prognostic biomarkers of Bacillus Calmette‐Guérin therapy failure in bladder cancer patients: A systematic review

Molecular Oncology, EarlyView.
High‐risk bladder cancer is typically treated with Bacillus Calmette‐Guérin (BCG), but 30–40% of patients relapse. No FDA‐ or CE‐approved biomarkers currently predict or prognosticate BCG failure. We systematically reviewed the literature and identified 72 eligible studies, revealing several promising biomarkers associated with BCG treatment response ...
Rui Ribeiro‐Pereira, Ana Teixeira‐Marques, Rui Freitas, João A Carvalho, Sara Monteiro‐Reis, Giorgio I. Russo, Rui Henrique, Carmen Jerónimo   +7 more
wiley   +1 more source

Prognostic value of risk factors in cervical squamous cell carcinoma based on tumour infiltration depth. [PDF]

BMC Cancer
Yang Q, Han X.
europepmc   +1 more source

How to promote the healthy development of continuous participation in smart medical and elderly care systems: The dual perspective of perceived value and risk. [PDF]

Digit Health, 2023
Cao C, Dai H, Li D.
europepmc   +1 more source

Worst-Case Value at Risk of Nonlinear Portfolios

Management Sciences, 2013
Steve Zymler, D. Kuhn, B. Rustem
semanticscholar   +1 more source